Nevertheless, although most etiologic studies of breast cancer emphasize ER, our molecular analysis allowed for analysis of both ER- and PR-associated targets across 2 developmental time points, elucidating important insights for both clinically utilized breast cancer biomarkers. This evidence concerns the gene ESR1 and breast cancer.